News
In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...
Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...
Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...
Pfizer’s Paxlovid is linked to far higher rate of COVID rebound: study Nov. 14, 2023 7:34 AM ET Pfizer Inc. (PFE) Stock By: Dulan Lokuwithana, SA News Editor 109 Comments ...
June 7 (Reuters) - A 15-day course of Pfizer's (PFE.N) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance Removes a Significant Uncertainty by Providing Pathway to U.S. Commercialization of Paxlovid on January ...
Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year.
21h
TipRanks on MSNWhy Pfizer’s (PFE) Oncology Gamble is Finally Paying Off
Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported ...
Pfizer says that a Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study has found that Paxlovid treatment reduces the risk of hospitalization or death by ...
Pfizer stuck by its full-year revenue forecast, predicting $98 billion to $102 billion in sales. Of that sum, the company still figures Comirnaty will contribute $32 billion, while Paxlovid will ...
Topline Paxlovid—Pfizer’s antiviral Covid-19 treatment—is 37% effective at preventing hospitalization or death in high-risk patients compared with no treatment, according to a study ...
Pfizer’s application is broadly in line with how Paxlovid is used under its EUA, which the company said covers an estimated 50% to 60% of the population who have at least one risk factor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results